Loading...
Market
Vyvgart Hytrulo market share in CIDP by end of 2024?
4
Resolution / Starting Odds
Less than 20% market share • 33%
20%-40% market share • 34%
More than 40% market share • 33%
Market analysis reports from reputable firms (e.g., IMS Health, EvaluatePharma)
Story
Argenx's Vyvgart Hytrulo Shot Gains Second FDA Approval for CIDP with Halozyme's ENHANZE
Jun 21, 2024, 09:10 PM
Argenx's Vyvgart Hytrulo shot has received its second US FDA approval to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare nervous system disorder. This approval marks a significant milestone for the biotechnology firm, which has faced a series of setbacks. The Vyvgart Hytrulo shot is co-formulated with Halozyme's ENHANZE technology. This label expansion into CIDP adds to Argenx's growth prospects ahead of more clinical milestones anticipated in 2024.
View original story
Similar markets
Market leader • 33%
Second place • 33%
Third place or lower • 33%
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Over 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Less than 20% • 25%
20% - 40% • 25%
40% - 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%